PL2992020T3 - Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 - Google Patents

Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1

Info

Publication number
PL2992020T3
PL2992020T3 PL14791494T PL14791494T PL2992020T3 PL 2992020 T3 PL2992020 T3 PL 2992020T3 PL 14791494 T PL14791494 T PL 14791494T PL 14791494 T PL14791494 T PL 14791494T PL 2992020 T3 PL2992020 T3 PL 2992020T3
Authority
PL
Poland
Prior art keywords
effector cells
antigen receptor
chimeric antigen
immune effector
engineered immune
Prior art date
Application number
PL14791494T
Other languages
English (en)
Inventor
Jianhua Yu
Craig HOFMEISTER
Jianhong CHU
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of PL2992020T3 publication Critical patent/PL2992020T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
PL14791494T 2013-05-03 2014-05-02 Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 PL2992020T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US201361876492P 2013-09-11 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells
EP14791494.9A EP2992020B1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells

Publications (1)

Publication Number Publication Date
PL2992020T3 true PL2992020T3 (pl) 2020-06-01

Family

ID=51844005

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14791494T PL2992020T3 (pl) 2013-05-03 2014-05-02 Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1

Country Status (17)

Country Link
US (3) US10358494B2 (pl)
EP (2) EP2992020B1 (pl)
JP (3) JP6856188B2 (pl)
KR (1) KR102098985B1 (pl)
CN (2) CN115028735A (pl)
AU (2) AU2014259675B2 (pl)
BR (1) BR112015027567B1 (pl)
CA (1) CA2910666A1 (pl)
DK (1) DK2992020T3 (pl)
ES (1) ES2777940T3 (pl)
HK (1) HK1218925A1 (pl)
HU (1) HUE048312T2 (pl)
IL (1) IL242315B (pl)
MX (1) MX370173B (pl)
PL (1) PL2992020T3 (pl)
PT (1) PT2992020T (pl)
WO (1) WO2014179759A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
CA2969704C (en) * 2014-12-05 2023-05-02 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
WO2016123142A1 (en) 2015-01-26 2016-08-04 The University Of Chicago IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
JP6849600B6 (ja) * 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
AU2016219785B2 (en) 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
WO2016164370A1 (en) * 2015-04-06 2016-10-13 Ohio State Innovation Foundation Egfr-directed car therapy for glioblastoma
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
CA2987290C (en) * 2015-06-10 2023-10-03 Nantkwest, Inc. Modified nk-92 cells for treating cancer
WO2017030370A1 (ko) 2015-08-17 2017-02-23 서울대학교산학협력단 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
EP3360961B1 (en) * 2015-10-08 2023-11-22 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
CN109715174A (zh) * 2016-01-15 2019-05-03 埃图比克斯公司 用于t细胞免疫治疗的方法和组合物
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
CN109414512A (zh) 2016-04-22 2019-03-01 科济生物医药（上海）有限公司 用于细胞免疫疗法的组合物和方法
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
EP3558368A4 (en) 2016-12-23 2020-12-30 MacroGenics, Inc. ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE
WO2018128485A1 (ko) * 2017-01-05 2018-07-12 한국생명공학연구원 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
MX2019011225A (es) * 2017-03-20 2020-01-21 Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
AU2018251150B2 (en) 2017-04-13 2024-05-09 Albert-Ludwigs-Universität Freiburg New sequence specific reagents targeting CCR5 in primary hematopoietic cells
US20200129554A1 (en) * 2017-07-07 2020-04-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated cd28 costimulatory domains
US11639508B2 (en) 2017-07-14 2023-05-02 The Johns Hopkins University Engineered TSC2
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
JP2021500875A (ja) * 2017-10-06 2021-01-14 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ キメラ抗原受容体
US20210371540A1 (en) * 2018-03-16 2021-12-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated cd28 phosphorylation sites
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
WO2020010341A1 (en) * 2018-07-05 2020-01-09 Emory University Transduction of innate immunocompetent cells using aav6
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
EP3894011A1 (en) 2018-12-11 2021-10-20 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
AU2020235865A1 (en) 2019-03-08 2021-09-23 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
KR20210148293A (ko) 2019-04-03 2021-12-07 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
CN114450308A (zh) 2019-06-12 2022-05-06 黑曜石疗法公司 用于调节性调控的ca2组合物和方法
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
WO2021092560A1 (en) * 2019-11-08 2021-05-14 Humanigen, Inc. Epha3 directed car-t cells for treatment of tumors
US20230242641A1 (en) * 2020-06-29 2023-08-03 Julius-Maximilians-Universität Würzburg Slamf7 cars
WO2022031602A1 (en) * 2020-08-06 2022-02-10 Promab Biotechnologies, Inc. Cs1- antibody and anti-cs1-car-t cells
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
HUP0300919A2 (hu) * 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
JP2012507555A (ja) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗ｃｓ１抗体の使用
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9073990B2 (en) 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
NO3012268T3 (pl) * 2010-09-08 2018-04-14
BR112013012138B1 (pt) * 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
MX347078B (es) * 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
EP2765193B1 (en) * 2011-10-07 2017-08-09 Mie University Chimeric antigen receptor
CA2855746A1 (en) 2011-11-16 2013-05-23 John Stephen HILL Methods of treating epidermal growth factor deletion mutant viii related disorders
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014089514A1 (en) 2012-12-07 2014-06-12 Solazyme, Inc. Genetically engineered microbial strains including chlorella protothecoides lipid pathway genes
CN103224561A (zh) 2013-01-16 2013-07-31 天津大学 葡萄球菌肠毒素小分子抗体及制备方法及用途
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CA3092355A1 (en) * 2018-03-16 2019-09-19 Cytoimmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy

Also Published As

Publication number Publication date
US11845794B2 (en) 2023-12-19
JP7221338B2 (ja) 2023-02-13
CA2910666A1 (en) 2014-11-06
US20200002418A1 (en) 2020-01-02
US10358494B2 (en) 2019-07-23
PT2992020T (pt) 2020-02-28
BR112015027567A2 (pt) 2017-12-05
EP2992020A1 (en) 2016-03-09
BR112015027567B1 (pt) 2024-02-20
EP2992020A4 (en) 2016-12-28
CN115028735A (zh) 2022-09-09
CN105377897A (zh) 2016-03-02
HUE048312T2 (hu) 2020-07-28
JP2021177771A (ja) 2021-11-18
AU2019203823B2 (en) 2021-05-13
JP2019146579A (ja) 2019-09-05
AU2019203823A1 (en) 2019-06-20
WO2014179759A1 (en) 2014-11-06
EP2992020B1 (en) 2020-01-15
AU2014259675A1 (en) 2015-11-12
US10227409B2 (en) 2019-03-12
US20170320941A1 (en) 2017-11-09
JP2016524598A (ja) 2016-08-18
HK1218925A1 (zh) 2017-03-17
KR102098985B1 (ko) 2020-04-09
DK2992020T3 (da) 2020-02-10
ES2777940T3 (es) 2020-08-06
JP6856188B2 (ja) 2021-04-07
MX2015015182A (es) 2016-05-05
KR20160003071A (ko) 2016-01-08
IL242315B (en) 2020-07-30
AU2014259675B2 (en) 2019-05-02
MX370173B (es) 2019-12-04
US20160075784A1 (en) 2016-03-17
EP3663320A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
HK1218925A1 (zh) -特異性嵌合抗原受體工程化的免疫效應細胞
IL290459A (en) Modified t cells - targeted chimeric antigen receptor cs1
HK1222186A1 (zh) 嵌合抗原受體
HK1215267A1 (zh) 嵌合抗原受體
HK1213922A1 (zh) 嵌合抗原受體
HK1222678A1 (zh) 特異性嵌合抗原受體及其用途
EP3087101A4 (en) Regulatable chimeric antigen receptor
EP3057991B8 (en) Chimeric antigen receptor t cell switches and uses thereof
HK1212728A1 (zh) 多鏈嵌合抗原受體和其用途
EP3057994A4 (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
EP2866833A4 (en) CRYSTALLINE ANTIBODIES AGAINST HUMAN IL-23
EP2765193A4 (en) CHIMERIC ANTIGEN RECEPTOR
EP2997134A4 (en) APPLICATION TO HUMANS OF T CELLS COMPRISING A CHIMERIC ANTIGENIC RECEPTOR (CAR)
PL2821416T3 (pl) Nowe przeciwciało przeciwko ludzkiemu receptorowi IL-23
ZA201508068B (en) Cd19 specific chimeric antigen receptor and uses thereof
GB201310565D0 (en) Antigen immunogenicity characterisation assay